PARP1 and pancreatic neoplasm: As expected, the gemcitabine and ABT-263 combination treatment promoted the death of the gemcitabine-treated and chemoresistant Capan2 pancreatic cancer cells according to blue trypan assay (Fig. 4b-c) and PARP1 cleavage (Fig. 4d).